Page 272 - Haematologica - Vol. 105 n. 6 - June 2020

K. Halaburda et al.
References
1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 Trial. Blood. 1998;92(7):2322-2333.
2. Solh M, Yohe S, Weidorf D, Ustun C. Core- binding factor acute myeloid leukemia: het- erogeneity, monitoring and therapy. Am J Hematol. 2014;89(12):1121-1131.
3. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221.
4. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4): 424-447.
5. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haeamtol. 2006;135(2):165-173.
6. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741-3750.
7. Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(24):5705-5717.
8. Mosna F, Papayannidis C, Martinelli G, et al. Complex karyotype, older age, and reduced first-line dose intensity determine poor sur- vival in core binding factor acute myeloid leukemia patients with long-term follow-up. Am J Hematol. 2015;90(6):515-523.
9. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213-2223.
10. LiuYin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk strat- ification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14):2826-2835.
11. Cairoli R, Beghini A, Turrini M, et al. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta. Am J Hematol. 2013;88(7):594-600.
12. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumors and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant. 2015;50(8):1037-1056.
13. Bacigalupo A, Ballen K, Rizzo D, et al.
Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
14. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse- free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610-611.
15. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA- matched sibling donors. Transplantation. 1974;18(4):295-304.
16. Hospital MA, Prebet T, Bertoli S, et al. Core- binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML intergroup. Blood. 2014;124(8):1312-1319.
17. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplanta- tion in first remission. J Clin Oncol. 2013;31(10):1293-1301.
18. Hübel K, Weingart O, Naumann F, et al. Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guide- lines and recommendations. Leuk Lymph. 2011;52(3):444-457.
19. Joon JH, Kim JW, Jeon YW, et al. Identification of molecular and cytogenetic risk factors for unfavorable core-binding fac- tor-positive adult AML with post-remission treatment outcome analysis including trans- plantation. Bone Marrow Transpl. 2014;49 (12):1466-1474.
20. Kuwatsuka W, Miyamura K, Suzuki R, et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood. 2009;113(9):2096-2103.
21. Hoyos M, Nomdedeu JF, Esteve J, et al. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. Eur J Haematol. 2013;91(3):209-218.
22. Duployez N, Marceau-Renaut A, Boissel N, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127(20):2451-2459.
23. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoi- etic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813-1821.
24. Qin YZ, Wang Y, Xu LP, et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell trans- plantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol. 2017;10(1):44.
25. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinet- ics in NPM1c, PML-RARA, RUNX1- RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115(2):198- 205.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
O’Donnell MR, Tallman MS, Abboud CN, et al. NCCN Guidelines version 2.2018. Acute myeloid leukemia. Cited 2018, 15 Sept. Available from https://www.nccn.org/ professionals/physician_gls/pdf/aml.pdf Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comor- bidity index and Karnofsky performance status are independent predictors of morbid- ity and mortality after allogeneic nonmye- loablative hematopoietic cell transplanta- tion. Cancer. 2008;112(9):1992-2001. Sengsayadeth S, Gatwood KS, Boumendil A, et al. Conditioning intensity in secondary AML with prior myelodysplastic syn- drome/myeloproliferative disorders: an EBMT ALWP study. Blood Adv. 2018;2(16):2127-2135.
Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syn- dromes. J Clin Oncol. 2017;35(11):1154- 1161.
Bornhäuser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus stan- dard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first com- plete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13(10):1035-1044.
Couriel DR, Saliba RM, Giralt S, et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplanta- tion. Biol Blood Marrow Transplant. 2004;10(3):178-185.
Jacobsen N, Badsberg JH, Lönnqvist B, et al. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-trans- plant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant. 1990;5(6):413-418. Ljungman P, Brand R, Hoek J, et al. Donor cytomegalovirus status influences the out- come of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis. 2014;59(4):473-481.
Poiret T, Axelsson-Robertson R, Remberger M, et al. Cytomegalovirus-specific CD8+ T- cells with different T-cell receptor affinities segregate T-cell phenotypes and correlate with chronic graft-versus-host disease in patients post-hematopoietic stem cell trans- plantation. Front Immunol. 2018;9:760. Battipaglia G, Ruggeri A, Labopin M, et al. Refined graft-versus-host disease/relapse- free survival in transplant from HLA-identi- cal related or unrelated donors in acute myeloid leukemia. Bone Marrow Transplant. 2018;53(10):1295-1303.
Faber ZJ, Chen X, Gedman AL, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48(12):1551-1556.
1730
haematologica | 2020; 105(6)